Dr Alastair Wilkins (BA, MB,BChir, PhD(Cantab)) is Reader in Neurology, University of Bristol, and Consultant Neurologist at Southmead Hospital, Bristol, UK. He researches axonal injury in multiple sclerosis and related disorders.

“This book would be most useful to general neurologists and neurology residents, as they would be most likely to care for patients with progressive multiple sclerosis. The book meets the needs of the intended audience … . This is a useful and needed book that concisely summarizes recent clinical trial data on new treatments for progressive multiple sclerosis. There are not many books that address this and therefore neurologists will find this one a useful addition to their library.” (Rashmi B. Halker Singh, Doody's Book Reviews, March, 2018)

• General introduction.- What is disease progression?- Clinical scales of disease progression and disability.- Primary progressive MS.- Epidemiology of progressive multiple sclerosis.- The neuropathology of progressive multiple sclerosis.- Mechanisms of disease progression.- Axonal injury.- Imaging disease progression.- Biomarkers of disease progression.- Symptomatic treatment for progressive multiple sclerosis.- Trials of licenced RRMS disease modifying therapies in progressive MS.- Trials of novel therapies specifically for progressive MS.- Rehabilitation.- Future therapies for progressive multiple sclerosis.

Dr Alastair Wilkins (BA, MB,BChir, PhD(Cantab)) is Reader in Neurology, University of Bristol, and Consultant Neurologist at Southmead Hospital, Bristol, UK. He researches axonal injury in multiple sclerosis and related disorders.

“This book would be most useful to general neurologists and neurology residents, as they would be most likely to care for patients with progressive multiple sclerosis. The book meets the needs of the intended audience … . This is a useful and needed book that concisely summarizes recent clinical trial data on new treatments for progressive multiple sclerosis. There are not many books that address this and therefore neurologists will find this one a useful addition to their library.” (Rashmi B. Halker Singh, Doody's Book Reviews, March, 2018)

• General introduction.- What is disease progression?- Clinical scales of disease progression and disability.- Primary progressive MS.- Epidemiology of progressive multiple sclerosis.- The neuropathology of progressive multiple sclerosis.- Mechanisms of disease progression.- Axonal injury.- Imaging disease progression.- Biomarkers of disease progression.- Symptomatic treatment for progressive multiple sclerosis.- Trials of licenced RRMS disease modifying therapies in progressive MS.- Trials of novel therapies specifically for progressive MS.- Rehabilitation.- Future therapies for progressive multiple sclerosis.

Dr Alastair Wilkins (BA, MB,BChir, PhD(Cantab)) is Reader in Neurology, University of Bristol, and Consultant Neurologist at Southmead Hospital, Bristol, UK. He researches axonal injury in multiple sclerosis and related disorders.

“This book would be most useful to general neurologists and neurology residents, as they would be most likely to care for patients with progressive multiple sclerosis. The book meets the needs of the intended audience … . This is a useful and needed book that concisely summarizes recent clinical trial data on new treatments for progressive multiple sclerosis. There are not many books that address this and therefore neurologists will find this one a useful addition to their library.” (Rashmi B. Halker Singh, Doody's Book Reviews, March, 2018)

• General introduction.- What is disease progression?- Clinical scales of disease progression and disability.- Primary progressive MS.- Epidemiology of progressive multiple sclerosis.- The neuropathology of progressive multiple sclerosis.- Mechanisms of disease progression.- Axonal injury.- Imaging disease progression.- Biomarkers of disease progression.- Symptomatic treatment for progressive multiple sclerosis.- Trials of licenced RRMS disease modifying therapies in progressive MS.- Trials of novel therapies specifically for progressive MS.- Rehabilitation.- Future therapies for progressive multiple sclerosis.